





# The MD Anderson Manual of Medical Oncology

**THIRD EDITION**



**HAGOP M. KANTARJIAN  
ROBERT A. WOLFF**

**Mc  
Graw  
Hill  
Education**



# The MD Anderson Manual of Medical Oncology

### **NOTICE**

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

# The MD Anderson Manual of Medical Oncology

Third Edition

Editors

## **Hagop M. Kantarjian, MD**

Professor of Medicine  
Chair, Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

## **Robert A. Wolff, MD**

Professor of Medicine  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas



New York Chicago San Francisco Athens London Madrid Mexico City  
Milan New Delhi Singapore Sydney Toronto

## **The MD Anderson Manual of Medical Oncology, Third Edition**

Copyright © 2016 by McGraw-Hill Education. All rights reserved. Printed in China. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous editions copyright © 2011, 2006 by The McGraw-Hill Companies, Inc.

1 2 3 4 5 6 7 8 9 0 DSS/DSS 20 19 18 17 16

ISBN 978-0-07-184794-0

MHID 0-07-184794-4

This book was set in Stempel Schneidler by Cenveo® Publisher Services.  
The editors were Karen G. Edmonson and Robert Pancotti.  
The production supervisor was Catherine H. Saggese.  
Project management was provided by Raghavi Khullar, Cenveo Publisher Services.  
The text designer was Eve Siegel; the cover designer was Dreamit, Inc.  
RR Donnelley was the printer and binder.

Cover photo: Main campus of MD Anderson Cancer Center. Copyright © 2016 The University of Texas MD Anderson Cancer Center.

The authors wish to acknowledge the exceptional administrative and organizational contributions of Ann M. Sandler, without whom this project would not have been completed.

## **Library of Congress Cataloging-in-Publication Data**

Names: Kantarjian, Hagop, 1952- , editor. | Wolff, Robert A., 1957- , editor. | University of Texas M.D. Anderson Cancer Center.

Title: The MD Anderson manual of medical oncology / editors, Hagop M. Kantarjian, Robert A. Wolff.

Other titles: Manual of medical oncology | Medical oncology

Description: Third edition. | New York : McGraw-Hill Education, [2016] |

Includes bibliographical references and index.


Identifiers: LCCN 2015041642 | ISBN 9780071847940 (hardcover) | ISBN 0071847944 (hardcover)

Subjects: | MESH: Neoplasms. | Medical Oncology—methods.

Classification: LCC RC262.5 | NLM QZ 200 | DDC 616.99/4—dc23 LC record available at <http://lcn.loc.gov/2015041642>

McGraw-Hill Education books are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To contact a representative, please visit the Contact Us pages at [www.mhprofessional.com](http://www.mhprofessional.com).

# Dedication



**Charles A. Koller, MD**  
**1948-2013**

This third edition of *The MD Anderson Manual of Medical Oncology* is dedicated to Charles A. Koller, a valued member of MD Anderson's Leukemia Department for nearly three decades, a committed physician, and an editor of the first and second editions of *The MD Anderson Manual of Medical Oncology*.



# Contents

*Contributors* xi  
*A Brief History of MD Anderson Cancer Center* xxi  
*Foreword* xxv  
*Preface* xxvii

## I LEUKEMIA

Section Editor: William G. Wierda

- 1. Acute Lymphoblastic Leukemia 3**  
*Muhamed Baljevic, Elias Jabbour, Susan O'Brien, Hagop M. Kantarjian*
- 2. Adult Acute Myeloid Leukemia 19**  
*Jasleen K. Randhawa, Joseph Khoury, Farhad Ravandi-Kashani*
- 3. Chronic Lymphocytic Leukemia and Associated Disorders 41**  
*Nitin Jain, Carlos Bueso-Ramos, Susan O'Brien, William G. Wierda*
- 4. Chronic Myeloid Leukemia 61**  
*Muhamed Baljevic, Elias Jabbour, Jorge Cortes, Hagop M. Kantarjian*
- 5. Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach 81**  
*Carlos Bueso-Ramos, Guillermo Garcia-Manero*
- 6. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms 103**  
*Srdan Verstovsek, Kate J. Newberry, Hesham M. Amin*

## II LYMPHOMA AND MYELOMA

Section Editor: Nathan H. Fowler

- 7. Indolent Lymphomas 133**  
*Loretta J. Nastoupil, Chan Yoon Cheah, L. Jeffrey Medeiros, Nathan H. Fowler*
- 8. Aggressive B-Cell Lymphomas 153**  
*Jason R. Westin, Sergej N. Konoplev, Luis E. Fayad, L. Jeffrey Medeiros*
- 9. T-Cell Lymphomas 181**  
*Dai Chihara, Casey Wang, Madeleine Duvic, L. Jeffrey Medeiros, Yasuhiro Oki*

## 10. Hodgkin Lymphoma 201

*Dai Chihara, Fredrick B. Hagemeister, L. Jeffrey Medeiros, Michelle L. Fanale*

## 11. Multiple Myeloma and Other Plasma Cell Dyscrasias 229

*Hans C. Lee, Krina Patel, Piyanuch Kongtim, Simrit Parmar, Pei Lin, Muzaffar H. Qazilbash, Sheeba Thomas, Elisabet E. Manasanch*

## III STEM CELL TRANSPLANTATION

Section Editor: Elizabeth J. Shpall

- 12. Autologous Hematopoietic Progenitor Cell Transplantation 257**  
*Riad El Fakih, Nina Shah, Yago Nieto*
- 13. Allogeneic Transplantation 267**  
*Jonathan E. Brammer, Borje S. Andersson, Chitra Hosing*
- 14. Alternative Donor Transplants: Cord Blood Transplant 291**  
*Rohtesh S. Mehta, Betul Oran, Elizabeth J. Shpall*
- 15. Alternative Donor Transplants: Haploidentical Hematopoietic Stem Cell Transplantation 301**  
*Sameh Gaballa, Richard E. Champlin, Stefan O. Ciurea*
- 16. Cellular Therapy in Allogeneic Hematopoietic Cell Transplantation 307**  
*Philip A. Thompson, Katayoun Rezvani, Partow Kebriaei*

## IV LUNG CANCER

Section Editor: Bonnie S. Glisson

- 17. Small Cell Carcinoma of the Lung 323**  
*Tina Cascone, Kathryn A. Gold, Bonnie S. Glisson*
- 18. Non-Small Cell Lung Cancer 343**  
*Diogo Bugano Diniz Gomes, Kathryn A. Gold, Don L. Gibbons, Commentary: George A. Eapen*



## V HEAD AND NECK CANCER

Section Editor: Bonnie S. Glisson

### 19. Head and Neck Cancer 379

Jennifer McQuade, G. Brandon Gunn, William Nassib William Jr., Merrill S. Kies

## VI GASTROINTESTINAL CANCERS

Section Editor: Robert A. Wolff

### 20. Gastric, Gastroesophageal Junction, and Esophageal Cancers 401

Elena Elimova, Roopma Wadhwa, Nikolaos Charalampakis, Alexandria T. Phan, Prajnam Das, M. Blum Murphy

### 21. Pancreatic Cancer 439

Jennifer B. Goldstein, Rachna T. Shroff, Robert A. Wolff, Milind M. Javle

### 22. Hepatocellular Carcinoma 463

Marc Uemura, Sunil Krishnan, Ahmed O. Kaseb, Nishin A. Bhadkamkar, Milind M. Javle, Rony Avritscher

### 23. Small Bowel Cancer and Appendiceal Tumors 479

Michael J. Overman, Kanwal Raghav, Christopher Lieu, Commentary: Keith F. Fournier

### 24. Colorectal Cancer 501

Van Morris, Ishwaria M. Subbiah, Scott Kopetz, Cathy Eng

### 25. Anal Cancer 525

Van Morris, Christopher Crane, Cathy Eng

### 26. Neuroendocrine Tumors 537

Daniel M. Halperin, James C. Yao

## VII BREAST CANCER

Section Editor: Gabriel N. Hortobagyi

### 27. Early-Stage and Locally Advanced Breast Cancer 551

Aron S. Rosenstock, Gabriel N. Hortobagyi

### 28. Metastatic Breast Cancer 573

Meghan Karuturi, Vicente Valero, Mariana Chavez-MacGregor

### 29. Inflammatory Breast Cancer 599

Tamer M. Fouad, Vicente Valero, Naoto T. Ueno

### 30. Special Situations in Breast Cancer 623

Stacy Moulder-Thompson, Zahi Mitri

## VIII GYNECOLOGIC MALIGNANCIES

Section Editor: Karen H. Lu

### 31. Ovarian Cancer 641

Kari L. Ring, Jubilee Brown, Amir A. Jazaeri

### 32. Tumors of the Uterine Corpus 665

Michaela A. Onstad, Janelle B. Pakish, Karen H. Lu

### 33. Tumors of the Uterine Cervix 689

Maria D. Iniesta, Kathleen M. Schmeler, Pedro T. Ramirez

### 34. Gestational Trophoblastic Disease 709

Jubilee Brown

## IX GENITOURINARY MALIGNANCIES

Section Editor: Nizar M. Tannir

### 35. Renal Cell Carcinoma 733

Matthew T. Campbell, Eric Jonasch, Christopher G. Wood, Nizar M. Tannir

### 36. Bladder Cancer 753

Arlene Siefker-Radtke, Bogdan A. Czerniak, Colin P. N. Dinney, Commentary: David J. McConkey

### 37. Prostate Cancer 773

Mehmet A. Bilen, Christopher J. Logothetis, Paul G. Corn

### 38. Penile Cancer 793

Lance C. Pagliaro

### 39. Testicular Cancer 807

Lance C. Pagliaro, Maryam N. Shafaei, Nizar M. Tannir

## X NEUROLOGIC TUMORS

Section Editors: John de Groot and Michael Fisch

### 40. Tumors of the Central Nervous System 829

Shiao-Pei Weathers, Barbara O'Brien, John de Groot, Commentary: Anita Mahajan, Commentary: Sujit S. Prabhu

## XI MALIGNANT MELANOMA AND SARCOMAS

Section Editors: Michael A. Davies and Sapna P. Patel

### 41. Melanoma 857

Dae Won Kim, Jeffrey E. Gershenwald, Sapna P. Patel, Michael A. Davies

**42. Soft Tissue and Bone Sarcomas 875**

*J. Andrew Livingston, Anthony Conley, Vinod Ravi,  
Shreyaskumar Patel*

**XII OTHER TUMORS**

*Section Editors: Michael Fisch and John de Groot*

**43. Endocrine Malignancies 903**

*Lily Kwatampora, Steven Weitzman,  
Mouhammed Habra, Naifa L. Busaidy*

**44. The Acquired Immunodeficiency Syndrome–Related Cancers 933**

*Adan Rios, Fredrick B. Hagemeister*

**XIII NOVEL AND OTHER CANCER TOPICS OF INTEREST**

*Section Editors: Apostolia-Maria Tsimberidou and  
Nizar M. Tannir*

**45. Carcinoma of Unknown Primary 961**

*Gauri R. Varadhachary*

**46. Pediatric Cancers 977**

*Ryuma Tanaka, Patrick A. Zweidler-McKay*

**47. Cancer Genomics 985**

*Jennifer Goldstein, Zhijing Zhang, Andy Futreal*

**48. Immuno-Oncology 995**

*Sangeeta Goswami, James P. Allison, Padmanee Sharma*

**49. Targeted Therapy in Cancer 1003**

*Apostolia-Maria Tsimberidou*

**50. Applied Biostatistics 1021**

*Xuelin Huang*

**XIV SUPPORTIVE CARE**

*Section Editor: Karen H. Lu*

**51. Fungal and Viral Infections in Cancer Patients 1031**

*Bruno P. Granwehr, Roy F. Chemaly, Dimitrios P. Kontoyiannis*

**52. Endocrine and Metabolic Complications of Cancer Therapy 1055**

*Levent Ozsari, Naifa Lamki Busaidy,  
Mouhammed Amir Habra*

**53. Oncologic Emergencies 1073**

*Sai-Ching Jim Yeung, Ellen F. Manzullo*

**54. Onco-Cardiology 1099**

*Elie Mouhayar, Danielle El-Haddad, Peter Kim, Kara  
Thompson*

**55. Pulmonary Complications of Cancer Therapy 1121**

*Saadia A. Faiz, Horia B. Grosu, Vickie R. Shannon*

**56. Cancer-Associated Thrombosis 1147**

*Rachel A. Sanford, Michael H. Kroll*

**XV PALLIATIVE CARE AND SYMPTOM MANAGEMENT**

*Section Editors: Eduardo Bruera and Michael Fisch*

**57. Palliative and Supportive Care 1159**

*David Hui, Eduardo Bruera*

**58. Pain Management and Symptom Control 1169**

*Kaoswi Shih, Rony Dev, Suresh K. Reddy*

**59. Rehabilitation 1189**

*Sunny S. Dhah, Jack B. Fu, Ki Y. Shin*

**60. Long-Term Survivorship in Adult and Pediatric Cancer 1211**

*Ravin Ratan, Joann Ater, Alyssa G. Rieber,  
Maria Alma Rodriguez*

*Index 1227*



# Contributors

**James P. Allison, PhD**

Professor of Immunology  
Chair, Department of Immunology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Hesham M. Amin, MD**

Professor of Hematopathology Adm.  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Borje Andersson, MD, PhD**

Professor of Stem Cell Transplantation  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Joann Ater, MD**

Professor of Pediatrics  
Department of Pediatrics  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Rony Avritscher, MD**

Associate Professor  
Interventional Radiology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Muhamed Baljevic, MD**

Fellow, Hematology and Medical Oncology  
Department of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Nishin A. Bhadkamkar, MD**

Assistant Professor  
General Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Mehmet A. Bilen, MD**

Fellow, Cancer Medicine - Fellowship Program  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jonathan E. Brammer, MD**

Instructor  
Department of Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jubilee Brown, MD**

Department of Gynecologic Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Eduardo Bruera, MD**

Department of Palliative Care and Rehabilitation Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Carlos Bueso-Ramos, MD, PhD**

Professor of Hematopathology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Naifa Lamki Busaidy, MD**

Associate Professor of Endocrine Neoplasia and HD  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Matthew T. Campbell, MD**

Assistant Professor of Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Tina Cascone, MD, PhD**

Fellow, Hematology and Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Richard E. Champlin, MD**

Chairman of Department of Stem Cell Transplantation  
and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Nikolaos Charalampakis, MD, PhD**

Former Postdoctoral Fellow  
 Department of Gastrointestinal Medical Oncology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas  
 Oncology Unit, Department of 2nd Internal Medicine  
 Propedeutics  
 Attikon University Hospital - National Kapodistrian University of  
 Athens  
 Athens, Greece

**Chan Yoon Cheah, MBBS, DMedSc**

Fellow, Lymphoma and Myeloma Research  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Roy F. Chemaly, MD, MPH, FIDSA, FACP**

Professor of Medicine  
 Chair, Infection Control Committee  
 Department of Infectious Diseases,  
 Infection Control, and Employee Health  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Dai Chihara, MD**

Fellow, Leukemia  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Stefan O. Ciurea, MD**

Associate Professor  
 Department of Stem Cell Transplantation and Cellular Therapy  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Anthony Conley, MD**

Assistant Professor  
 Department of Sarcoma Medical Oncology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Paul G. Corn, MD, PhD**

Associate Professor of Genitourinary Medical Oncology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Jorge Cortes, MD**

Jane and John Justin Distinguished Chair in Leukemia Research  
 Chief, CML and AML Sections  
 Deputy Chair, Department of Leukemia  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Christopher H. Crane, MD**

Professor  
 Program Director and Section Chief, Gastrointestinal Section  
 Department of Radiation Oncology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Bogdan Czerniak, MD, PhD**

Professor of Pathology  
 Department of Pathology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Prajnam Das, MD**

Associate Professor, Radiation Oncology Department  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Michael A. Davies, MD, PhD**

Department of Melanoma Medical Oncology  
 Department of Systems Biology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Rony Dev, DO**

Associate Professor, Palliative Care Medicine  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Sunny S. Dhah, DO**

Fellow, Department of Palliative Care and Rehabilitation  
 Medicine  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Colin P. N. Dinney, MD**

Chair Department of Urology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Madeleine Duvic, MD**

Professor of Medicine and Dermatology  
 Blanche Bender Professorship in Cancer Research  
 Deputy Chair, Department of Dermatology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**George A. Eapen, MD**

Professor of Pulmonary Medicine  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Elena Elimova, MD, MSc, FRCPC**

Staff Physician, Division of Medical Oncology Assistant Professor,  
 Department of Medicine University of Toronto Princess  
 Margaret Cancer Centre  
 Toronto, Ontario

**Cathy Eng, MD, FACP**

Professor  
 Associate Medical Director, Colorectal Center  
 Director, Network Clinical Research, Gastro-intestinal  
 Medical Oncology  
 Department of Gastrointestinal Medical Oncology  
 The University of Texas MD Anderson Cancer Center  
 Houston, Texas

**Saadia A. Faiz, MD**

Associate Professor of Pulmonary Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Michelle Fanale, MD**

Associate Professor of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Luis E. Fayad, MD**

Associate Professor of Medicine  
Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Tamer M. Fouad, MD, PhD**

Assistant Professor (Adjunct)  
Department of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Keith Fournier, MD**

Assistant Professor of Surgery  
Department of Surgical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Nathan H. Fowler, MD**

Associate Professor  
Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jack B. Fu, MD**

Assistant Professor  
Department of Palliative Care and Rehabilitation Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Andy Futreal, PhD**

Chair Ad Interim of Genomic Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sameh Gaballa, MD, MS**

Fellow, Department of Stem Cell Transplantation  
and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Guillermo Garcia-Manero, MD**

Professor of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jeffrey E. Gershenwald, MD**

Department of Surgical Oncology  
Department of Cancer Biology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Don L. Gibbons, PhD**

Assistant Professor  
Department of Thoracic/Head and Neck Medical Oncology,  
Department of Molecular and Cellular Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Bonnie S. Glisson, MD**

Professor of Medicine  
Thoracic/Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kathryn A. Gold, MD**

Assistant Professor  
Department of Thoracic/Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jennifer B. Goldstein, MD**

Instructor of Gastrointestinal Medical Oncology-Research  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Diogo Bugano Diniz Gomes, MD**

Medical Oncology  
Hospital Israelita Albert Einstein  
Brazil

**Sangeeta Goswami, MD, PhD**

Fellow, Medical Oncology  
Department of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Bruno P. Granwehr, MD, MS**

Associate Professor of Infectious Diseases  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**John de Groot, MD**

Department of Neuro-Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Horiana B. Grosu, MD**

Assistant Professor of Pulmonary Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**G. Brandon Gunn, MD**

Associate Professor  
Department of Radiation Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Mouhammed Amir Habra, MD**

Associate Professor  
Department of Endocrine Neoplasia and Hormonal Disorders  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Danielle El-Haddad, MD**

Clinical Research Resident  
Department of Cardiology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Fredrick B. Hagemeister, MD**

Professor of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Daniel M. Halperin, MD**

Assistant Professor  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Gabriel N. Hortobagyi, MD, FACP, FASCO**

Professor, Department of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Chitra Hosing, MD**

Professor of Medicine  
Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Xuelin Huang, PhD**

Professor  
Department of Biostatistics  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**David Hui, MD, MSc**

Department of Palliative Care and Rehabilitation Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Maria D. Iniesta**

Senior Coordinator of Research Data, Gynecology  
Oncology and Reproductive Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Elias Jabbour**

Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Nitin Jain, MD**

Assistant Professor  
Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Milind M. Javle, MD**

Professor  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Amir A. Jazaeri, MD**

Department of Gynecologic Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Faye Johnson, MD, PhD**

Associate Professor of Thoracic/Head and  
Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Eric Jonasch, MD**

Professor of Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Hagop M. Kantarjian, MD**

Professor of Medicine  
Chair, Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Meghan Karuturi, MD**

Assistant Professor of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ahmed Kaseb, MD**

Associate Professor  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Partow Kebriaei, MD**

Department of Stem Cell Transplantation and Cellular Therapy  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Joseph Khoury, MD**

Assistant Professor of Hematopathology Adm.  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Merrill S. Kies, MD**

Clinical Professor of Thoracic/Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Dae Won Kim, MD**

Department of Melanoma Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Peter Kim, MD**

Assistant Professor of Medicine  
Department of Cardiology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Piyanuch Kongtim, MD**

Department of Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sergej N. Konoplev, MD, PhD**

Associate Professor  
Department of Hematopathology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Dimitrios P. Kontoyiannis, MD, ScD**

Professor of Infectious Disease  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Scott Kopetz, MD, PhD.**

Associate Professor of Gastro-Intestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sunil Krishnan, MD**

Professor  
Department of Radiation Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Michael H. Kroll**

Section of Benign Hematology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Lily Kwatampora, MBChB, MPH**

Fellow, Clinical Research  
Department of Endocrinology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Hans C. Lee, MD**

Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Christopher H. Lieu, MD**

Assistant Professor of Medicine  
University of Colorado Cancer Center  
Aurora, Colorado

**Pei Lin, MD**

Department of Hematopathology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**J. Andrew Livingston, MD**

Fellow, Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Christopher J. Logothetis, MD**

Chair, Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Karen H. Lu, MD**

Chair and Professor, Department of Gynecologic Oncology and  
Reproductive Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Anita Mahajan, MD**

Department of Radiation Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Mariana Chavez-MacGregor, MD**

Assistant Professor of Health Services Research-Clinical  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Elisabet E. Manasanch, MD, MHSc**

Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ellen F. Manzullo, MD, FACP**

Professor of Medicine  
Deputy Division Head (Clinical)  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**David J. McConkey, PhD**

Professor of Urology Research  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jennifer L. McQuade, MD**

Fellow, Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**L. Jeffrey Medeiros, MD**

Chair and Professor, Department of Hematopathology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Rohtesh S. Mehta, MD, MPH, MS**

Fellow, Department of Stem Cell Transplantation  
and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Zahi Mitri, MD**

Fellow, Hematology and Medical Oncology  
Department of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas



**Van Morris, MD**

Assistant Professor, Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Elie Mouhayar, MD, FACC, FSVM**

Associate Professor of Medicine  
Department of Cardiology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Stacy Moulder-Thompson, MD, MSCI**

Associate Professor  
Chief, Section of Clinical Research and Drug Development  
Department of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**M. Blum Murphy, MD**

Assistant Professor of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Loretta J. Nastoupil, MD**

Assistant Professor  
Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kate J. Newberry**

Senior Research Scientist of Leukemia Research  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Barbara O'Brien, MD**

Department of Neuro-Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Susan O'Brien, MD**

Associate Director for Clinical Science  
Chao Family Comprehensive Cancer Center  
Medical Director  
Sue and Ralph Stern Center for Clinical Trials and Research  
Professor of Medicine  
Division of Hematology/ Oncology  
Department of Medicine  
University of California  
Irvine, California

**Yasuhiro Oki, MD**

Associate Professor  
Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Michaela A. Onstad, MD**

Fellow, Gynecologic Oncology and Reproductive Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Betul Oran, MD**

Assistant Professor  
Department of Stem Cell Transplantation and Cellular Therapy  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Michael J. Overman, MD**

Associate Professor of Medicine  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Levent Ozsari**

Istanbul, Turkey

**Lance C. Pagliaro, MD**

Professor of Oncology  
Mayo Clinic College of Medicine  
Senior Associate Consultant  
Department of Oncology, Division of Medical Oncology  
Mayo Clinic  
Rochester, Minnesota

**Janelle B. Pakish, MD**

Fellow, Gynecologic Oncology and Reproductive Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Simrit Parmar, MD**

Department of Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Krina Patel, MD**

Department of Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sapna P. Patel, MD**

Department of Melanoma Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Shreyaskumar Patel, MD**

Professor  
Department of Sarcoma Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Alexandria T. Phan, MD**

Professor, Gastrointestinal Medical Oncology  
Hematology-Oncology  
Houston Methodist Cancer Center  
Houston, Texas

**Katherine M. Pisters, MD**

Professor of Thoracic/Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sujit S. Prabhu, MD**

Department of Neurosurgery  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Muzaffar H. Qazilbash, MD**

Department of Stem Cell Transplantation and Cellular Therapy  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kanwal Raghav, MD**

Assistant Professor of Medicine  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Pedro T. Ramirez, MD**

Professor  
Director of Minimally Invasive Surgical Research and Education  
Department of Gynecologic Oncology and Reproductive  
Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jasleen K. Randhawa, MD**

Fellow, Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ravin Ratan, MD**

Fellow, Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Farhad Ravandi-Kashani, MD**

Professor of Medicine  
Chief, Section of Developmental Therapeutics  
Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Vinod Ravi, MD**

Associate Professor  
Department of Sarcoma Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Suresh K. Reddy, MD**

Professor of Palliative Care Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Katayoun Rezvani, MD, PhD**

Department of Stem Cell Transplantation and Cellular Therapy  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Alyssa G. Rieber, MD**

Assistant Professor  
Department of Oncology  
Lyndon B. Johnson Hospital  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kari L. Ring, MD**

Department of Gynecologic Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Adan Rios, MD**

Associate Professor of Medicine  
Oncologist, Division of Oncology  
Department of Internal Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Maria Alma Rodriguez, MD**

Vice President, Medical Affairs  
Professor  
Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Aron S. Rosenstock, MD**

Fellow, Clinical  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Rachel A. Sanford**

Section of Benign Hematology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kathleen M. Schmeler, MD**

Associate Professor of Gynecology,  
Oncology and Reproductive Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Maryam N. Shafaei, MD**

Fellow, Cancer Medicine - Fellowship Program  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Vickie R. Shannon, MD**

Professor of Medicine  
Director, Pulmonary Rehabilitation Program  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Padmanee Sharma, MD, PhD**

Professor of Genitourinary Medical Oncology and Immunology  
Department of Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kaoswi Shih, MD**

Hospice and Palliative Medicine Fellow  
Department of Palliative Care and Rehabilitation Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ki Y. Shin, MD**

Professor, Rehabilitation Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Elizabeth J. Shpall, MD**

Professor  
Department of Stem Cell Transplantation and Cellular Therapy  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Rachna Shroff, MD**

Assistant Professor  
Department of Gastro-Intestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Arlene O. Siefker-Radtke, MD**

Associate Professor of Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ishwaria M. Subbiah**

Fellow, Palliative Care Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Ryuma Tanaka, MD**

Department of Pediatrics-Patient Care  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Nizar M. Tannir, MD, FACP**

Professor of Medicine  
Deputy Chair, Department of Genitourinary Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sheeba Thomas, MD**

Department of Lymphoma and Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Kara Thompson, MD**

Assistant Professor of Medicine  
Department of Cardiology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Philip A. Thompson, MD**

Department of Leukemia  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Apostolia-Maria Tsimberidou, MD, PhD**

Department of Investigational Cancer Therapeutics  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Marc Uemura, MD, MBA**

Fellow, Hematology and Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Naoto T. Ueno, MD, PhD, FACP**

Professor of Medicine  
Executive Director of Morgan Welch Inflammatory Breast Cancer  
Research Program and Clinic  
Department of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Vicente Valero, MD**

Professor of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Gauri R. Varadhachary, MD**

Professor  
Department of Gastrointestinal Medical Oncology  
Medical Director  
Gastrointestinal Medical Center  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Srdan Verstovsek, MD, PhD**

Professor of Medicine  
Director, Hanns A. Pielenz Clinical Research Center  
for Myeloproliferative Neoplasms  
Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Roopma Wadhwa, MD, MHA**

Oklahoma Health Sciences Center  
Oklahoma, Oklahoma

**Casey Wang**

University of Alabama  
Tuscaloosa, Alabama

**Shiao-Pei Weathers, MD**

Department of Neuro-Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Steven P. Weitzman, MD**

Assistant Professor of Medicine  
Department of Endocrine Neoplasia and Hormonal Disorders  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Jason R. Westin, MD**

Assistant Professor of Lymphoma/Myeloma  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**William G. Wierda, MD, PhD**

Professor of Medicine  
Center Medical Director  
CLL Section Chief  
Department of Leukemia  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**William N. William Jr., MD**

Associate Professor  
Head and Neck Section Chief  
Department of Thoracic and Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Robert A. Wolff, MD**

Professor of Medicine  
Department of Gastrointestinal Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Christopher G. Wood, MD**

Professor of Urology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**James C. Yao, MD**

Chair and Professor, Department of Gastrointestinal  
Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Sai-Ching Jim Yeung, MD, PhD**

Professor of Emergency Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, Texas

**Zhijing Zhang**

Fellow, Post-doctoral  
The University of Texas Health Science Center at Houston  
Houston, Texas

**Patrick A. Zweidler-McKay, MD, PhD**

Associate Professor  
Section Chief for Pediatric Leukemia and Lymphoma  
Division of Pediatrics  
The University of Texas MD Anderson Cancer Center  
Houston, Texas



# A Brief History of MD Anderson Cancer Center

Houston's evolution into the fourth largest city in the United States was propelled by four seminal events. First was the Great Galveston Hurricane of 1900, which destroyed the city port of Galveston and led to the realization that Houston could become a viable and safer deep-water port; this led to the widening of the Ship Channel to offer direct access to Houston. Second was the discovery of oil at Spindletop in Beaumont, Texas in 1901. This prompted the development of the oil industry in Texas and transformed Houston from a small town into a large city. Third was (of course) the commercialization of air conditioning in 1950's, which made Houston (and many Southern cities of the United States) more livable. And lastly, the allocation of land for the Texas Medical Center created the largest medical center in the world with one of the highest densities of clinical facilities for patient care, basic science, and translational research. The Texas Medical Center is a major contributor to Houston's economy and growth.

Several additional factors contributed to the creation of The University of Texas MD Anderson Cancer Center in Houston and its development into one of the most important cancer centers in the world. First was the generous philanthropy of visionary Texans such as Monroe Dunaway Anderson (Fig. 1) (his nephew died of leukemia in 1936) and his partner Will Clayton, who founded the charitable MD Anderson Foundation, which helped create the Texas Medical Center in 1945. The charter



**FIGURE 1.**



**FIGURE 2.**

of the Anderson Foundation did not specify how the money should be used, but Mr. Anderson's trustees and close friends—Colonel William Bates, John Freeman and Horace Williams—leaned strongly in favor of health care. Soon after taking possession of the estate from its executors, the trustees turned to Dr. Ernest Bertner (Fig. 2) for advice. Dr. Bertner was a

prominent Houston surgeon and gynecologist who was well known to the trustees because of his care for cancer patients, despite inadequate facilities and treatment options (he was later called the “father of the Texas Medical Center”).

The trustees and Dr. Bertner noted that the 1941 Texas legislature authorized the University of Texas to create a hospital for cancer research and treatment, allocating \$500,000 for the purpose. Today, that figure would be approximately \$8 million. The Anderson trustees, with Dr. Bertner's guidance, seized the opportunity and offered to match the \$500,000 legislative appropriation, if the hospital was to be named for Monroe Dunaway Anderson and located in Houston. The legislature accepted their offer. The trustees then purchased 134 acres of mosquito-infested land to create the Texas Medical Center, stating that the new cancer hospital would be located there. They made it known that the new state hospital should be an academic institution. In fact, MD Anderson was the first comprehensive cancer hospital to be associated with a major university as an independent free-standing unit.

In 1942, The University of Texas Board of Regents appointed Dr. Bertner as the director of the new hospital. A 6-acre property near downtown was purchased from the estate of Captain James A. Baker, grandfather of former Secretary of State James Baker III, and became the first campus of the hospital. An empty

carriage house became the office and stables were the research laboratories. Twelve surplus army barracks were procured for patient clinics (Figs. 3A-C). With the addition of 22 leased beds at Hermann Hospital, the dream became reality, and the “MD Anderson Hospital and Tumor Institute” was created. A small



**FIGURE 3A.**



**FIGURE 3B.**



**FIGURE 3C.**

faculty of physicians and scientists was recruited from the University of Texas Medical Branch in Galveston, and cancer patients finally had a home. It was renamed “MD Anderson Hospital for Cancer Research” in 1942.

In 1946, Dr. Bertner persuaded Dr. Randolph Lee Clark, a native Texan, to become president of what was to become The University of Texas MD Anderson Cancer Center. Dr. Clark, a widely recognized surgeon,

concentrated on recruiting an excellent surgical faculty and then set upon acquiring all the basic and clinical scientists and clinicians. From the outset, all efforts, whether administrative, clinical or research, were focused on developing excellence in research-driven cancer care. Forty-six patients were receiving treatment in these early quarters when the hospital moved to its current site in March 1954 (Figs. 4A and B).



**FIGURE 4A.**



**FIGURE 4B.**





FIGURE 5.



FIGURE 6A.

Additional resources to expand the MD Anderson infrastructure (Fig. 5) and research capacities came from several venues: (1) generous donations from the oil industry; (2) the visionary research and administrative leadership under its four presidents, Drs. Randolph Lee Clark (1946–1978) (Fig. 6A), Charles A. LeMaistre (1978–1996) (Fig. 6B), John Mendelsohn (1996–2011) (Fig. 6C), and Ronald DePinho (2011–present) (Fig. 6D); (3) the recruitment of world-renowned cancer research pioneers (some of the early legends included Drs. Emil J. Freireich, Emil Frei, Gilbert Fletcher, James Butler, Felix Rutledge, Gerald Dodd, and Sidney Wallace); and (4) the relentless research efforts of the cancer experts on the MD Anderson’s faculty.



FIGURE 6B.



FIGURE 6C.



FIGURE 6D.

in numerous discoveries that became standards of care across many types of cancers, and that have saved the lives and/or improved survivals and outcomes of millions of patients with cancer around the world.

One component of MD Anderson’s mission is to spread its knowledge about cancer research and discoveries across the globe. This educational mission is furthered by the hematology/oncology fellowship that currently trains more than 40 medical hematology-oncology cancer specialists on its premises. *The MD Anderson Manual of Medical Oncology*, created as part of our educational mission, is written by our fellows as first authors and supported in depth by senior tumor specialty faculty

as co-authors. We envision this third edition expanding into a continuously updated electronic version that educates and spreads knowledge and discoveries in cancer research and therapy rapidly and widely.

Today, MD Anderson is one of the largest cancer centers in the world, with more than 21,000 employees and 1800 faculty; serving more than 150,000 patients with cancer in Houston every year; operating a 700-bed cancer hospital; and being ranked as the No. 1 hospital for cancer care by the *U.S. News and World Report* in 11 of the past 14 years. The MD Anderson Cancer Center research has resulted

Charles A. LeMaistre, M.D.  
 John Mendelsohn, M.D.  
 Ronald A. DePinho, M.D.

# Foreword

*The MD Anderson Manual of Medical Oncology*, third edition, articulates the personalized, multidisciplinary approach to cancer management pioneered by the University of Texas MD Anderson Cancer Center. This approach has contributed to our ranking as number one in cancer care in 11 of the past 14 years in the *US News & World Report's* “America’s Best Hospitals” survey. Our unique perspective has evolved from decades of clinical practice and research with more than a million patients treated. The book is designed to bring a pragmatic approach to cancer management that may serve as a guide for oncologists around the world. The text reflects how MD Anderson currently operates, including many patient care practices that would not have been recognized by practitioners just a decade ago. In a single year, 96,500 people with cancer—33,200 of them new patients—seek care at MD Anderson. Since the first edition, we have improved our ability to identify biomarkers that are predictive for survival, a major triumph in medical oncology that is demonstrated throughout the text.

The current edition emphasizes and discusses recent developments in precision medicine and immunotherapies.

Reflecting new advances in our approach to cancer management, the third edition of *The MD Anderson Manual of Medical Oncology* features several new chapters. For example, there are new chapters on important aspects of stem cell transplantation: cord blood transplant, haploidentical stem cell transplantation, and cellular therapy in allogeneic hematopoietic cell transplantation. In addition, new chapters on pediatric cancers, molecular biomarkers and cancer, immuno-oncology, targeted therapies in cancer, applied biostatistics, oncocardiology, pulmonary complications of cancer therapy, and cancer-associated thrombosis have been added.

To help clinicians quickly assess cancer management options, every chapter includes abundant tables, diagrams, and imaging photos. These include, for example, treatment algorithms and decision trees developed at MD Anderson for specific cancers or disease subtypes; promising novel therapy targets and the latest clinical trial phase of drugs targeting them; and new molecular therapies recommended to overcome resistance to previously effective therapies.

The new era of novel personalized, targeted therapeutics has also sparked the recent evolution of another crucial advancement in management of metastatic disease: the transition from sequential care culminating in the sole delivery of palliative care, to integration of ongoing active disease treatment with simultaneous interdisciplinary symptom control, palliative care, and rehabilitation to improve quality of life. Clinicians at MD Anderson no longer approach advanced metastatic disease management with palliative care goals alone; now, these patients are often offered frontline cancer treatment and the opportunity to participate in clinical trials for investigational drugs.

In recognition of the growing pool of patients who are surviving their cancer, MD Anderson has greatly expanded programs for cancer survivors since the publication of the first edition.

Waun Ki Hong, MD  
American Cancer Society Professor  
Samsung Distinguished University Chair Emeritus in  
Cancer Medicine  
Former Division Head, Cancer Medicine  
Professor, Thoracic/Head and Neck Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, Texas  
May 2016



# Preface

When we first envisioned *The MD Anderson Manual of Medical Oncology*, we hoped that it would fill an important void in oncology reference material by serving as a hands-on resource for the practicing oncologist. The first edition, published in 2006, was written exclusively by our faculty and fellows with the idea of giving a bird's-eye view of how multidisciplinary care was practiced at our institution. We were proud of that initial effort and pleased that the book received positive reviews from several high-impact journals, including *JAMA*, *The Lancet*, and *The New England Journal of Medicine*.

The second edition, published in 2011, moved closer to the aims of providing more illustrations, figures, tables, and algorithms. In addition, the second edition included new chapters on myelodysplastic syndromes, Philadelphia chromosome-negative myeloproliferative neoplasms, T-cell lymphomas, small bowel cancer and appendiceal tumors, inflammatory breast cancer, and penile cancer.

In the third edition, we have continued the tradition of including evidence-based management algorithms in the form of flowcharts and diagrams, shaped by the clinical experience of our world-class faculty at MD Anderson. Readers are also provided with a practical

guide to the diagnostic and therapeutic strategies used at MD Anderson.

The new edition of *The MD Anderson Manual of Medical Oncology* contains new chapters on cord blood transplant, haploidentical stem cell transplantation, cellular therapy in allogeneic hematopoietic cell transplantation, pediatric cancers, molecular biomarkers and cancer, immuno-oncology, targeted therapies in cancer, applied biostatistics, oncocardiology, pulmonary complications of cancer therapy, and cancer-associated thrombosis. In addition, there is expanded coverage of the rapidly growing areas of biological and immune therapies of cancer.

The new edition of *The MD Anderson Manual of Medical Oncology* will also be a continually updated version of the book, online, with the latest science and clinical recommendations from the world-renowned clinical investigators at MD Anderson.

We hope that this edition serves to help oncologists everywhere provide high-quality, state-of-the-art cancer care to their patients.

Hagop M. Kantarjian, MD  
Robert A. Wolff, MD



## Section I

# Leukemia

Section Editor: William G. Wierda

- 1 Acute Lymphoblastic Leukemia
- 2 Adult Acute Myeloid Leukemia
- 3 Chronic Lymphocytic Leukemia and Associated Disorders
- 4 Chronic Myeloid Leukemia
- 5 Myelodysplastic Syndromes: The MD Anderson Cancer Center Approach
- 6 Philadelphia-Chromosome Negative Myeloproliferative Neoplasms



# Acute Lymphoblastic Leukemia

Muhamed Baljevic  
Elias Jabbour  
Susan O'Brien  
Hagop M. Kantarjian

## EPIDEMIOLOGY AND ETIOLOGY

Acute lymphoblastic leukemia (ALL) is characterized by the proliferation and accumulation of lymphoid progenitor cells in the blood, bone marrow, and other tissues. It has a bimodal distribution. The overall age-adjusted incidence is 1.7 per 100,000 persons, but ALL affects 4 to 5 per 100,000 persons during age 4 to 5 years and half that number around the fifth decade of life. Approximately 60% of cases are diagnosed in patients  $\leq 20$  years old, with a median age at diagnosis of 14 years. In 2014, the American Cancer Society estimated that approximately 6,000 individuals would be diagnosed with ALL that year<sup>(1,2)</sup>. Acute lymphoblastic leukemia represents 20% of adult leukemias but is the most common childhood acute leukemia, representing approximately 80% of cases<sup>(1,2)</sup>.

The etiology of ALL is unknown in most cases<sup>(3-7)</sup>. Chromosomal translocations occurring in utero during fetal hematopoiesis have suggested genetic factors as the primary cause for pediatric ALL and postnatal genetic events as secondary contributors. Monozygotic and dizygotic twins of patients with ALL and individuals with genetic disorders, such as Klinefelter (XXY and variants) and Down (trisomy 21) syndromes, or inherited diseases with excessive chromosomal fragility, such as Bloom syndrome, Fanconi anemia, and ataxia telangiectasia, have all been found to have higher incidence of ALL, implicating a possible genetic predisposition. Additional studies have postulated infectious etiologies<sup>(4)</sup>. Human T-cell lymphotropic

virus type-1 is known to cause adult T-cell leukemia/lymphoma<sup>(5)</sup>; Epstein-Barr virus has been associated with lymphoproliferative disorders, including Burkitt lymphoma and mature B-cell ALL<sup>(6)</sup>; and varicella has been linked to childhood ALL<sup>(7)</sup>.

## CLINICAL PRESENTATION AND LABORATORY ABNORMALITIES

Presenting symptoms can be nonspecific, particularly in children. They largely reflect bone marrow failure and include malaise, fatigue, bleeding or bruising, and secondary infections. The B symptoms, such as fever, night sweats, and weight loss, are frequent. White blood cell (WBC) count at presentation varies widely, and circulating blasts are generally noted. Symptoms related to hyperleukocytosis are rare in ALL, given the lymphoblast morphology, even when WBC counts are high.

Leukemic involvement of the central nervous system (CNS) ranging from cranial neuropathies to meningeal infiltration occurs in  $<10\%$  of patients at presentation. It is more common in mature B-cell ALL (Burkitt leukemia)<sup>(8)</sup>. A history or findings of abdominal masses, significant spontaneous tumor lysis syndrome, and chin numbness (mental nerve) indicating cranial nerve involvement are also more common in this subtype of ALL<sup>(9)</sup>. Lymphadenopathy and hepatosplenomegaly, although rarely symptomatic, are noted in approximately 20% of patients<sup>(9)</sup>.



## DIAGNOSIS

### Immunophenotyping

The diagnosis of ALL is largely based on flow cytometric immunophenotyping, although identification of cytogenetic-molecular abnormalities plays a significant role (Fig. 1-1). The World Health Organization (WHO) proposed new guidelines for the diagnosis of neoplastic diseases of hematopoietic and lymphoid tissues<sup>(10)</sup>. The French-American-British (FAB) Cooperative Group diagnostic approach, which recognizes L1 to L3 morphologic subtypes, has been essentially abandoned. A blast count of  $\geq 20\%$  was established as sufficient for diagnosis.

Flow cytometric analysis successfully assigns lineage in more than 95% of cases. True mixed phenotype acute leukemia is rare<sup>(11)</sup>. Concomitant expression of markers from more than one lineage is seen in 15% to 50% of adult and 5% to 35% of pediatric ALL<sup>(12-14)</sup>, but this is not prognostically relevant. Targeted genomic profiling may further define ALL subtypes with different response profiles to therapy and prognoses, which are only partially discriminated by current diagnostic tools.


Immunophenotypically, ALL blasts are negative for myeloperoxidase (MPO), although low-level MPO positivity (3%-5%) may occur in rare cases that otherwise lack expression of myeloid markers by flow cytometry<sup>(15)</sup>. Terminal deoxynucleotidyl transferase

(TdT), although not a specific marker of ALL, helps separate malignant lymphocytosis from reactive processes and distinguish L3 ALL (TdT negative) from other ALL subtypes<sup>(16)</sup>.

Both the prior FAB and current WHO classification systems rely heavily on morphologic assessment<sup>(17)</sup>, which accounts for cell size, cytoplasm, nucleoli, basophilia, and vacuolation. The former FAB L3 morphology, characterized by a high rate of cell turnover, is associated with mature B-cell ALL (Burkitt leukemia) and gives rise to the “starry sky” pattern on marrow biopsies.

Three broad immunophenotypic ALL groups can be distinguished: precursor B-cell, mature B-cell, and T-cell ALL (Table 1-1). Precursor B-cell ALL (B-ALL) stains positive for TdT, HLA-DR, CD19, and CD79a. According to the stages of maturation, further B-cell subgroups have been defined as pre-pre-B-ALL (pro-B-ALL), common ALL, and pre-B-ALL. Although they all stain positive for CD19, CD79a, or CD22, expression of CD10 (common ALL antigen [CALLA]) distinguishes common ALL (early pre-B-ALL), and cytoplasmic immunoglobulins with or without CD10 identify pre-B-ALL. Mature B-ALL (Burkitt leukemia) is TdT negative but expresses surface immunoglobulins (usually immunoglobulin M), as well as  $\kappa$  or  $\lambda$  light chains in a clonal fashion. It has almost ubiquitous expression of CD20, which has therapeutic implications<sup>(18)</sup>.

T-cell ALL (T-ALL) further stratifies into subtypes based on different stages of thymic differentiation<sup>(19)</sup>.



<sup>1</sup>Low-level myeloperoxidase (MPO) positivity (3%-5%) may occur in rare cases that otherwise lack expression of myeloid markers by flow cytometry.

**FIGURE 1-1** Diagnosis of acute lymphoblastic leukemia. AML, acute myeloid leukemia.

**Table 1-1 Immunophenotypic Classification of ALL**

B Lineage		T Lineage	
CD19/CD79a/CD22		CD3 (Surface/Cytoplasmic)	
Pre-pre-B-ALL (pro-B-ALL)	—	Precursor T-ALL	CD1a, CD2, CD5, CD7, CD8, cCD3
Common ALL	CD10 (CALLA)	Mature T-ALL	Surface CD3 (plus any other T-cell markers)
Pre-B-ALL	Cytoplasmic IgM		
Mature B-ALL	Cytoplasmic or surface Ig $\kappa$ or $\lambda$		

As the most lineage-specific marker for T-cell differentiation, surface CD3 (sCD3) is typically positive in mature T-ALL, which is also positive for either CD4 or CD8, but not both. However, pre-T-ALL is negative for CD4, CD8, and sCD3 but may still express cytoplasmic CD3. A more simplified classification divides T-ALL into early T-ALL (sCD3<sup>-</sup>, CD1a<sup>-</sup>), thymic T-ALL (sCD3<sup>+/-</sup>, CD1a<sup>+</sup>), and mature T-ALL (sCD3<sup>+</sup>, CD1a<sup>+</sup>). Only thymic T-ALL has excellent outcome with chemotherapy alone.

### Cytogenetic-Molecular Profiling

Frequent cytogenetic and molecular abnormalities associated with adult ALL offer insight into the events leading to leukemic progression (Table 1-2)<sup>(20)</sup>. They are of both prognostic and predictive significance and have varying frequencies in children and adults, which explains some of the differences in outcomes in these two groups. This is particularly true in the case of ALL harboring Philadelphia chromosome [t(9;22)] (Ph) or

**Table 1-2 Cytogenetic and Molecular Abnormalities in ALL**

Category	Cytogenetics	Involved Genes	Adults Frequency (%)	Children Frequency (%)
Hyperdiploid			2-15	10-26
Hypodiploid			5-10	5-10
Pseudodiploid	t(9;22)(q34;q11)	<i>BCR-ABL1</i>	15-25	2-6
	del(9)(q21-22)	<i>p15, p16</i>	6-30	20
	t(4;11);t(9;11);	<i>MLL</i>	5-10	<5
	t(11;19); t(3;11)			
	del(11)(q22-23)	<i>ATM</i>	25-30 <sup>a</sup>	15 <sup>a</sup>
	t(12;21)(p12;q22)	<i>TEL-AML1</i>	<1 <sup>b</sup>	20-25 <sup>b</sup>
	t(1;19)	<i>E2A-PBX1</i>	<5	<5
	t(17;19)	<i>E2A-HLF</i>	<5	<5
	t(1;14)(p32;q11)	<i>TAL1</i>	10-15	5-10
	t(7;9)(q34;q32)	<i>TAL2</i>	<1	<1
	t(10;14)(q24;q11)	<i>HOX11</i>	5-10	<5
	t(5;14)(q35;q32)	<i>HOX11L2</i>	1	2-3
	t(1;14)(p32;q11)	<i>TCR</i>	20-25 <sup>c</sup>	20-25 <sup>c</sup>
	del(13)(q14)	<i>miR15/miR16</i>	<5	<5
	t(8;14); t(8;22); t(2;8)	<i>C-MYC</i>	5	2-5
	+8	?	10-12	2
	del(7p)	?	5-10	<5
	del(5q)	?	<2	<2
	del(6q); t(6;12)	?	5	<5

<sup>a</sup>As determined by loss of heterozygosity.

<sup>b</sup>As determined by polymerase chain reaction.

<sup>c</sup>In T-cell ALL, overall incidence <10%.


other chromosomal changes with prognostic relevance such as Burkitt karyotypes [t(8;14), t(2;8), t(8;22)] or t(4;11). Next-generation sequencing, expression proteomics, and oligonucleotide microarrays have transformed our understanding of the genomic landscape of ALL and are yielding new molecular subgroups with actionable defects<sup>(21-23)</sup>.

Recently, a Ph-like signature in 10% of children with standard-risk ALL and as many as 25% to 30% of young adults with ALL has been defined using genome-wide gene expression arrays. This subgroup lacks the expression of BCR-ABL1 fusion protein but does have a gene expression profile similar to BCR-ABL1 ALL<sup>(24-26)</sup>. The vast majority of these patients have deletions in key transcription factors involved in B-cell signaling, such as IKZF1, TCF3, EBF1, PAX5, and VPB1, as well as kinase-activating alterations involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving *FLT3*, *IL7R*, or *SH2B3*. The most common alterations (~50%) are rearrangements of CRLF2, which activate downstream signaling through JAK kinases, and approximately half of these cases have activating mutations in *JAK1* or *JAK2* (Fig. 1-2). Importantly, patients with ABL1, ABL2, CSF1R, and PDGFRB expression fusions were sensitive in vitro and in vivo human xenograft models to ABL class tyrosine kinase inhibitors (TKIs; eg, dasatinib); rearrangements in *EPOR*, *IL-7R*, and *JAK2* mutations and fusions were sensitive to JAK kinase inhibitors (eg, ruxolitinib); and patients with ETV6-NTRK3 fusion were sensitive to ALK kinase inhibitors (eg, crizotinib)<sup>(25)</sup>, further expanding therapeutic options in this subgroup with poor outcome.

Observations of epigenetic alterations regulating distinct molecular pathways that occur frequently at presentation and relapse have identified a “hypermethylator” phenotype of ALL<sup>(27)</sup>. These patients may respond favorably to treatment with hypomethylating agents (azacitidine or decitabine). Identification of these and other molecular and cytogenetic changes in adult ALL drives the development of risk-adapted and targeted therapies, particularly in high-risk groups (Table 1-3)<sup>(28)</sup>.

## FRONTLINE THERAPY

Therapy for ALL consists of complex and comprehensive regimens consisting of several phases: induction, intensified consolidation, maintenance, and CNS prophylaxis<sup>(9,29)</sup>. Each involves the use of a core group of agents considered the backbone of therapy in a time- and dose-dependent manner, with a goal of restoring normal hematopoiesis, eradicating resistant subclones, providing adequate prophylaxis of sanctuary sites (eg, CNS, testicles), and eliminating minimal residual disease (MRD) during the consolidation and maintenance phases<sup>(9,30)</sup>. Combining anthracyclines (eg, daunorubicin or doxorubicin), vincristine, and dexamethasone (for better CNS penetration), often coupled with cyclophosphamide or asparaginase with growth factor support, represents the cornerstone of ALL induction regimens. This results in complete remission (CR) rates of 70% to 90% and median remission durations of 18 months<sup>(30,31)</sup>. Patients who achieve CR subsequently transition to the consolidation phase, which, depending on the risk-oriented subtype, may consist of consolidation chemotherapy (cytarabine, methotrexate, cyclophosphamide, and 6-mercaptopurine) or allogeneic hematopoietic stem-cell transplantation (AH SCT). Consolidation is followed by prolonged maintenance therapy with daily 6-mercaptopurine, weekly methotrexate, and monthly pulses of vincristine and prednisone or dexamethasone, given over 2 to 3 years (POMP or DOMP, depending on corticosteroid used)<sup>(30-32)</sup>. Maintenance, which is omitted in mature B-ALL due to high cure rates, may also involve the use of TKIs for patients with Ph-positive ALL. Primary CNS involvement at diagnosis is rare (<10%) but is as high as 50% to 75% at 1 year without prophylactic administration of intrathecal chemotherapy (IT)<sup>(31)</sup>. Although high-dose cytarabine (1-7.5 mg/m<sup>2</sup>) and methotrexate (5-8 g/m<sup>2</sup>) successfully penetrate the blood-brain barrier, they are too toxic to serve as the sole CNS prophylaxis. The inclusion of IT prophylaxis (methotrexate, cytarabine, liposomal cytarabine, hydrocortisone, or thiotepa) reduces the incidence of CNS relapse to 4% by allowing sustained therapeutic concentration of the agents in the cerebrospinal fluid. The number of ITs varies according



**FIGURE 1-2** Ph-like acute lymphoblastic leukemia (ALL) molecular lesions and associated molecular fusions or mutations.

**Table 1-3 Recent Genetic Determinants in ALL by Lineage**

ALL Lineage	Cytogenetic Aberration	Involved Genes	Protein	Comments
B cell	BCR/ABL+ (Ph+)	<i>IKZF1</i>	Ikaros	Poor outcome. 80% of Ph+ cases.
		<i>CRLF2</i> + the Ig heavy chain locus; or an interstitial <i>PAR1</i> deletion	<i>CRLF2</i>	5%-10% of cases with no molecular rearrangement. Poor outcome. 50% of children with Down syndrome.
	BCR/ABL-like	<i>IKZF1</i> deletions; rearrangements/mutations in <i>CRLF2</i> , <i>IGH-CRLF2</i> , and <i>NUP214-ABL1</i> ; in-frame fusions of <i>EBF1-PDGFRB</i> , <i>BCR-JAK2</i> , or <i>STRN3-JAK2</i> ; cryptic <i>IGH-EPOR</i> rearrangements		15% of cases. Potential use of TKIs and/or mTOR and JAK2 inhibitors.
	Near hypodiploid	<i>NRAS</i> , <i>KRAS</i> , <i>FLT3</i> , and <i>NF1</i>		70% of cases.
	Low hypodiploid	<i>IKZF2</i> , and by <i>TP53</i> disruptions, <i>CDKN2A/B</i> locus deletion		91% of cases.
	Hyperdiploid	<i>CREBBP</i>		
		<i>NT5C2</i> mutations	<i>NT5C2</i>	
		<i>TP53</i> mutations		6% of cases.
T cell		<i>PICALM-MLL10</i> , <i>NUP214-ABL1</i> fusion, <i>EML-ABL1</i> , <i>SET-NUP214</i> fusion, <i>MLL</i> , <i>NOTCH1</i> , <i>FBW7</i> , <i>BCL11B</i> , <i>JAK1</i> , <i>PTPN2</i> , <i>IL7R</i> , <i>PHF6</i> , <i>RAS/PTEN</i>		<i>NOTCH1</i> (>60%) and/or <i>FBW7</i> (~20%) mutations associated with a favorable outcome. <i>RAS/PTEN</i> and <i>JAK1</i> usually poor outcome.

mTOR, mammalian target of rapamycin; TKI, tyrosine kinase inhibitor.

to protocol (usually 8 for standard risk, 12 for Ph positive, and 16 for Burkitt), and in rare cases of extramedullary disease spread (eg, masses or chloromas), IT may even be supplemented by radiation therapy.

One extensively studied regimen used in treatment of adult ALL is the hyper-CVAD (HCVAD) regimen, where patients receive hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine for a total of eight alternating cycles approximately every 3 to 4 weeks (Table 1-4)<sup>(30,31)</sup>. This is followed by 2 years of POMP maintenance therapy, interspersed with intensification courses during months 6, 7, 18, and 19. The number of IT injections (two per course) depends on the risk of CNS relapse, which has been identified as high for patients with mature B-ALL. Our current approach is giving 8 ITs for nonmature B-ALL and 16 ITs for mature B-ALL, resulting in a 5-year overall survival (OS) between 38% and 50%<sup>(30)</sup>. Due the improved cure rates of Ph-positive ALL patients, an increase in the CNS relapse rate was observed, which is the reason the protocol was modified to include 12 ITs for Ph-positive ALL.

### Mature B-Cell and Burkitt Acute Lymphoblastic Leukemia

The addition of rituximab to short intensive chemotherapy has also improved outcome in adult Burkitt

and Burkitt-type lymphoma or ALL<sup>(29, 33, 34)</sup>. Hoelzer and colleagues have recently reported the benefit of adding rituximab to short intensive chemotherapy in 363 patients with Burkitt lymphoma/leukemia; the addition of rituximab resulted in CR and 5-year survival rates of 88% and 80%, respectively<sup>(33)</sup>. Higher rates of survival were reported in adolescents compared to adults and elderly patients (90% vs 84% vs 62%, respectively)<sup>(33)</sup>. Low-intensity chemotherapy with infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) was recently tested in 30 adult patients with Burkitt lymphoma<sup>(35)</sup>. The progression-free survival (PFS) and OS rates were 90% and 100%, respectively. Of note, marrow involvement was present in only 13% of patients, and CNS involvement was present in only 3% of patients<sup>(35)</sup>.

### CD20-Positive Pre-B-Cell Acute Lymphoblastic Leukemia

There have been several alterations to traditional protocols with further refining of the disease. Expression of cell surface marker CD20 in adult ALL ranges from 35% to ubiquitous depending on the subtype and has been associated with an inferior prognosis<sup>(18)</sup>. The addition of two doses of monoclonal CD20 antibody

**Table 1-4 Doses and Schedule of the Hyper-CVAD Regimen**

Therapy Segment	Dose and Schedule
Induction and intensified consolidation	Hyper-CVAD (courses 1, 3, 5, and 7)
	• Cyclophosphamide 300 mg/m <sup>2</sup> IV over 3 h every 12 h for 6 doses on days 1-3
	• Mesna 600 mg/m <sup>2</sup> as an IV continuous infusion over 24 h daily on days 1-3 (starting approximately 1 h prior to cyclophosphamide and finishing 12 h after the last dose)
	• Doxorubicin 50 mg/m <sup>2</sup> IV continuous infusion over 24 h on day 4
	• Vincristine 2 mg IV on days 4 and 11
	• Dexamethasone 40 mg daily on days 1-4 and 4-11
	Methotrexate (MTX) and high-dose cytarabine (courses 2, 4, 6, and 8)
	• MTX 200 mg/m <sup>2</sup> IV over 2 h followed by 800 mg/m <sup>2</sup> IV over 22 h on day 1
	• Leucovorin rescue 15 mg every 6 h for eight doses (starting 12 h after completion of MTX)
	• Cytarabine 3 g/m <sup>2</sup> IV over 2 h every 12 h for 4 doses on days 2 and 3
CNS prophylaxis	• Methylprednisolone 50 mg IV twice daily on days 1-3
	IT MTX 12 mg (6 mg if via Omayo reservoir) on day 2 and cytarabine 100 mg on day 7 of each course
	Low risk: 6 IT
	High risk: 8 IT
Maintenance therapy	Mature B cell: 16 IT
	POMP
	• 6-Mercaptopurine 50 mg orally three times per day
	• MTX 20 mg/m <sup>2</sup> orally weekly
	• Prednisone 200 mg orally days 1-5 every month
Supportive care	• Vincristine 2 mg IV every month
	• Intensification with four additional courses of hyper-CVAD plus MTX/cytarabine
	• Antibiotic prophylaxis (levofloxacin, fluconazole, valacyclovir)
	• Hematopoietic growth factor support during induction and consolidation
	• Laminar air flow rooms (for patients ≥60 years old)

CNS, central nervous system; IT, intrathecal; IV, intravenous.

(rituximab) administered with the first four cycles of chemotherapy and during maintenance intensification at months 6 and 18 resulted in improved OS in younger patients compared with similar chemotherapy historical controls (75% vs 47% at 3 years;  $P = .003$ )<sup>(36)</sup>. Improvement in the 5-year remission duration and survival rates was also reported in patients <55 years old by the German Multicenter Study Group for ALL (GMALL) when rituximab was added to standard induction and consolidation therapy<sup>(37)</sup>.

Ofatumumab is a more potent second-generation anti-CD20 monoclonal antibody that binds to a membrane proximal small-loop epitope on the CD20 protein. A phase II study in CD20-positive pre-B-ALL combined ofatumumab with HCVAD during induction, resulting in a 96% rate of both CR and MRD negativity. At a median follow-up of 14 months, the 1-year PFS and OS rates were 94% and 92%, respectively<sup>(38)</sup>.

### Philadelphia-Positive Acute Lymphoblastic Leukemia

Philadelphia-positive ALL used to have a very poor outcome in general. The incorporation of TKIs into treatment regimens has significantly improved patient outcomes, as supported by several reports<sup>(39-42)</sup>. Incorporation of early, daily, and concurrent TKI with chemotherapy has proven more effective than intermittent pulses<sup>(41, 42)</sup>.

Second-generation TKIs, such as the dual src and abl inhibitor dasatinib, which is more potent than imatinib and crosses the blood-brain barrier<sup>(43)</sup>, have also been investigated in combination with chemotherapy. In an attempt to improve on the outcomes with imatinib, dasatinib was administered at 100 mg daily for 14 days with induction chemotherapy, followed by 70 mg continuous dosing with the consolidation cycles, and at

100 mg daily continuously during the maintenance phase<sup>(44)</sup>. Overall, 94% of patients achieved CR, 96% achieved complete cytogenetic response (CCyR), and 65% achieved complete molecular response (CMR). Allogeneic hematopoietic stem-cell transplantation was performed in 22 patients (12 in first CR and 10 in second CR), with 3-year disease-free survival (DFS) and OS rates of 49% and 61%, respectively.

Attempting to reduce exposure to cytotoxic chemotherapy by intensifying chemotherapy with TKIs can be very effective but toxic<sup>(45, 46)</sup>. Patients in the GRAAPH-2005 study were randomized to imatinib 800 mg daily for 4 weeks combined with weekly vincristine and dexamethasone versus imatinib 800 mg daily for 2 weeks combined with HCVAD chemotherapy<sup>(45)</sup>. The CR rate was higher in the low-intensity group due to induction-related mortality in the HCVAD group (7% vs <1%;  $P = .01$ ). An equal number of patients in each group proceeded to autologous stem cell transplantation and allogeneic stem cell transplantation, and at 3 years, OS was similar between the two arms (53% for low intensity vs 49% for HCVAD;  $P = .61$ ).

Studies have also evaluated the use of dasatinib and nilotinib with low-intensity chemotherapy<sup>(46-48)</sup>. In the EWALL-Ph-01 study, dasatinib with low-intensity chemotherapy was administered to 71 patients with newly diagnosed Ph-positive ALL age  $\geq 55$  years<sup>(46)</sup>. Dasatinib was dosed at 140 mg once daily during induction and at 100 mg daily during consolidation, yielding a CR rate of 94%. The estimated 3-year OS was 45%.

Many Ph-positive ALL patients can relapse with threonine-to-isoleucine mutation at position 315 (T315I), which is refractory to imatinib and second-generation TKIs. A third-generation TKI, ponatinib, which has activity against T315I, was evaluated in phase I and II trials in patients with Ph-positive leukemias and was shown to have significant antileukemic activity<sup>(49, 50)</sup>. More recently, 39 patients with newly diagnosed Ph-positive ALL were treated with HCVAD and ponatinib 45 mg daily for 14 days during induction and then continuously thereafter until CCyR and CMR were obtained, when decreases to 30 mg and 15 mg daily could be instituted, respectively. The CR, CCyR, and CMR rates were 100%, 100%, and 74%, respectively. After a median follow-up of 20 months, 1-year PFS and OS were 97% and 87%, respectively<sup>(51)</sup>.

Although current standard of care still advocates AHSCT consolidation in first CR<sup>(39)</sup>, new information regarding the status of MRD in Ph-positive ALL has raised a question as to who should be referred for it. The predictive value of MRD assessment by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and multiparameter flow cytometry (FCM) was recently assessed in patients with Ph-positive ALL treated with combination chemotherapy and TKIs who did not undergo AHSCT. Achieving major molecular

response at 3, 6, 9, and 12 months ( $P = .02, .04, .05$ , and  $.01$ , respectively) and having negative FCM at 3 and 12 months were associated with improved survival ( $P = .04$  and  $.001$ , respectively)<sup>(52)</sup>. This information suggests that patients with early and sustained molecular response may not need consolidation with AHSCT.

### T-Cell Acute Lymphoblastic Leukemia

Treatment of adult T-ALL and T-cell lymphoblastic lymphoma (T-LL) results in a long-term survival rate of 40% to 60%, and the outcome is strongly associated with T-cell phenotype<sup>(53, 54)</sup>. Adding nelarabine, a selective anti-T-ALL agent may further improve the outcome. In a single-arm, phase II study, 48 patients with newly diagnosed T-ALL or T-LL were treated with HCVAD and nelarabine<sup>(55)</sup>. The CR rate was 93%; the 5-year survival rate was 66% after a median follow-up of 41 months. These rates were 38% and 70% for patients with early T-cell precursor (ETP) and mature T-ALL, respectively. Indeed, ETP-ALL is a distinct T-cell entity characterized by the absence of CD1a, sCD3, and CD8 expression; weak CD5 expression; and expression of one or more myeloid or stem cell-associated markers<sup>(54)</sup>. It confers poor prognosis with the use of standard intensive chemotherapy, which results in high rates of remission failure and relapse compared to patients with typical T-ALL (72% at 10 years vs 10% at 10 years). This phenotype is in part a reflection of the higher degree of genomic instability (number and size of genetic defects) that ETP-ALL harbors, with over 60% of adult patients carrying mutations in *DNMT3A*, *FLT3*, or *NOTCH1*, which may allow for tailored induction regimens with targeted therapies<sup>(56)</sup>. Following induction, AHSCT should be considered in first remission for all ETP-ALL patients.

### Adolescent and Young Adult Acute Lymphoblastic Leukemia

Retrospective studies have shown that pediatric regimens resulted in better outcomes than adult regimens (which had deviated significantly from the established principles of ALL therapy in pediatric regimens). Pediatric-inspired regimens, such as the Berlin-Frankfurt-Münster (BFM) regimen (Table 1-5), deliver more intensive nonmyelosuppressive agents like vincristine, asparaginase, corticosteroids, and CNS therapy<sup>(54, 55)</sup>.

The Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) evaluated a pediatric-inspired regimen in patients up to age 60 years and compared the results to a historical control group treated with an adult regimen. In patients treated with the pediatric-inspired regimen, the CR rate was 93%, and at 42 months, event-free survival (EFS) and OS rates were 55% (95% CI, 48%-52%) and 60% (95% CI, 53%-66%), respectively<sup>(57)</sup>.

**Table 1-5 Doses and Schedule of the Augmented Berlin-Frankfurt-Münster (BFM) Regimen**

Therapy Segment	Dose and Schedule
Induction (4 weeks)	IT cytarabine 100 mg within 3 days prior to start of induction
	Daunorubicin 25 mg/m <sup>2</sup> IV weekly for 4 doses
	Vincristine 2 mg IV weekly for 4 doses
	Prednisone 60 mg/m <sup>2</sup> /d orally in divided doses on days 1-28
	PEG-asparaginase 2,500 international units/m <sup>2</sup> IV during week 1
	IT Methotrexate 12 mg during weeks 2 and 5
Extended induction (2 weeks)	Daunorubicin 25 mg/m <sup>2</sup> IV during week 1
	Vincristine 2 mg IV weekly for 2 doses
	Prednisone 60 mg/m <sup>2</sup> /day orally in divided doses for 14 days
	PEG-asparaginase 2500 international units/m <sup>2</sup> IV during week 1
Consolidation 1 (8 weeks)	Cyclophosphamide 1 g/m <sup>2</sup> IV during weeks 1 and 5
	Cytarabine 75 mg/m <sup>2</sup> subcutaneously or IV on days 1-4 and 8-11 of each month
	6-Mercaptopurine 60 mg/m <sup>2</sup> /day orally on days 1-14 of each month
	Vincristine 2 mg IV during weeks 3 and 4 of each month
	PEG-asparaginase 2500 international units/m <sup>2</sup> IV during weeks 3 and 6
	IT methotrexate 12 mg weekly for 4 weeks
Consolidation 2 (7 weeks)	Vincristine 2 mg IV every 10 days for 5 doses
	Methotrexate, starting at 100 mg/m <sup>2</sup> and escalating by 50 mg/m <sup>2</sup> /dose every 10 days for 5 doses
	PEG-asparaginase 2,500 IU/m <sup>2</sup> IV during weeks 1 and 4
	IT methotrexate 12 mg during weeks 1 and 5
Consolidation 3–part A (4 weeks)	Vincristine 2 mg IV weekly for 3 doses
	Dexamethasone 10 mg/m <sup>2</sup> /d orally in divided doses on days 1-7 and days 15-21
	Doxorubicin 25 mg/m <sup>2</sup> IV weekly for 3 doses
	PEG-asparaginase 2,500 IU/m <sup>2</sup> IV during week 1
Consolidation 3–part B (4 weeks)	IT methotrexate 12 mg during week 1
	Cyclophosphamide 1 g/m <sup>2</sup> IV during week 1
	Cytarabine 75 mg/m <sup>2</sup> subcutaneously or IV for 4 consecutive days during weeks 1 and 2
	Thioguanine 60 mg/m <sup>2</sup> /d orally for 14 days
	Vincristine 2 mg IV during weeks 3 and 4
Maintenance (24 months)	PEG-asparaginase 2,500 IU/m <sup>2</sup> IV during week 3
	IT methotrexate 12 mg during weeks 1 and 2
	Vincristine 2 mg IV monthly
	Dexamethasone 6 mg/m <sup>2</sup> /d orally for 5 days every month
	6-Mercaptopurine 75 mg/m <sup>2</sup> /d in divided doses
Supportive care	Methotrexate 20 mg/m <sup>2</sup> orally weekly
	IT methotrexate 12 mg every 3 months for the first 12 months of maintenance
	Antibiotic prophylaxis (levofloxacin, trimethoprim/sulfamethoxazole [start week 2 of induction], fluconazole, valacyclovir)

Slow early responders repeat consolidation 2 and consolidation 3A and 3B prior to maintenance therapy. If central nervous system disease is present at start of therapy, then give methotrexate 12 mg IT weekly until negative for blasts, methotrexate 12 mg IT every other week for 8 doses, and then methotrexate 12 mg IT monthly for 6 months.

IT, intrathecal; IV, intravenous.

Although the pediatric-inspired regimen resulted in improved survival compared with the control (66% vs 44%;  $P < .001$ ), the cumulative incidence of treatment-related death in patients age 40 to 60 years old was 23%, erasing the margin of benefit gained with enhanced activity of pediatric regimens. Thus, the toxicity threshold can be reached and crossed in the adult population in attempts to reach higher cure rates, limiting the usefulness of intensifying chemotherapy to the pediatric-inspired strength.

The UKALL14 study of 91 adults with a median age of 47 years (range, 25-65 years) used PEG-asparaginase at a dose of 1,000 units/m<sup>2</sup> on days 4 and 18 during induction, resulting in a CR rate of 66%, with induction-related mortality rate of 20% and hepatotoxicity rate of 56%, prompting the omission of PEG-asparaginase in patients  $\geq 40$  years old<sup>(58)</sup>.

A recent US Intergroup study of 318 adolescent and young adult (AYA) patients (median age, 24 years) treated with a pediatric-inspired regimen was reported. With a median follow-up of 28 months, the estimated 5-year EFS and OS rates were 45% and 55%, respectively<sup>(59)</sup>. Presence of MRD at day 28 following initiation of induction therapy and presence of a Ph-like gene expression signature were significantly associated with worse EFS and OS. The Ph-like signature, which was detected in 28% of patients, resulted in 2-year EFS of only 52%, compared to 81% for those without Ph-like disease.

Our internal review of 85 AYA patients up to age 40 (median age, 21 years) treated with pediatric-like augmented BFM showed CR and MRD negativity rates of 94% and 69%, respectively<sup>(60)</sup>. The 5-year CR rate was 58%, and the 5-year OS rate was 62%. Compared with a historical control group of similar patients who received HCVAD with or without rituximab, 3-year OS rates were 72% and 71%, respectively. However, in patients age 25 years and older, the pediatric-inspired regimen was inferior and caused more liver dysfunction, pancreatitis, osteonecrosis, and thrombosis compared to HCVAD with CD20-targeted therapies.

Hence, HCVAD-based regimens that use the backbone ALL agents but eliminate or reduce the exposure to asparaginase show similar CR and remission rates and survival outcomes compared with the pediatric-inspired regimens in similar patient populations.

### Acute Lymphoblastic Leukemia in Elderly Patients

Conventional ALL chemotherapy is associated with high mortality rates (30%-35%) during consolidation/maintenance in elderly patients ( $>60$  years)<sup>(60)</sup>. A low-intensity regimen may improve outcome. In a phase II study with inotuzumab ozogamicin and low-intensity hyper-CVD therapy, 26 patients with a median age of 67 years (range, 60-79 years) were treated for newly

diagnosed ALL<sup>(61)</sup>. Inotuzumab, which is a CD22-directed monoclonal antibody bound to calicheamicin (chemotoxin), was administered at a dose of 1.3 to 1.8 mg/m<sup>2</sup> once with each of the first four courses; doxorubicin was eliminated in induction; cyclophosphamide and steroids were 50% reduced; methotrexate was reduced to 250 mg/m<sup>2</sup> on day 1 and cytarabine to 0.5 mg/m<sup>2</sup>  $\times 4$  on days 2 and 3 of even courses. The overall response rate (ORR) was 96% (CR, 79%; CR with incomplete platelet recovery [CRp], 17%), with all patients with cytogenetic abnormalities achieving CCyR. All responders also achieved MRD-negative status, 75% of which occurred after cycle 1. The 1-year PFS and OS rates were 86% and 81%, respectively. The 1-year survival rate was superior to previous results obtained with HCVAD with or without rituximab in similar patient populations (1-year OS, 81% vs 60%, respectively).

### Role of Allogeneic Stem Cell Transplantation

Allogeneic stem cell transplantation has traditionally been reserved for patients with high-risk features including B-lineage with WBC  $\geq 30 \times 10^9/L$ , T-lineage with WBC  $\geq 100 \times 10^9/L$ , hypodiploid, Ph-positive, or mixed-lineage leukemia translocation ALL [eg, t(4;11)]. However, there has been some debate regarding who should be referred for AHSCT in first CR based on recent data that indicate that patients with standard-risk disease, and not high-risk disease, benefit the most<sup>(62)</sup>. As an alternative, many centers have incorporated MRD via FCM or RT-PCR after induction or consolidation to stratify patients based on their response to chemotherapy<sup>(63)</sup>. In fact, when controlled for other known risk factors, failure to achieve MRD has emerged as a powerful indicator of future relapse<sup>(62)</sup> and therapeutic approach (ie, AHSCT vs more chemotherapy). In one study, MRD status at various time points after CR was used to guide treatment in adult patients with ALL<sup>(64)</sup>. Patients who remained MRD positive at the end of consolidation were deemed to be higher risk and underwent AHSCT instead of receiving prolonged maintenance therapy. Patients who achieved MRD-negative status had a significantly improved 5-year OS (75% vs 33%;  $P = .001$ ). Furthermore, in a recent update of the GRAALL experience in 423 younger adults with Ph-negative ALL in first remission (265 B-cell precursor ALL and 158 T-ALL patients), postinduction MRD level  $\geq 10^{-4}$  and unfavorable genetic characteristics (ie, *MLL* gene rearrangement or focal *IKZF1* gene deletion in B-cell precursor ALL and no *NOTCH1/FBXW7* mutation and/or *N/K-RAS* mutation and/or *PTEN* gene alteration in T-ALL) were independently associated with worse outcome<sup>(65)</sup>. Therefore, for patients with standard-risk ALL, MRD status should guide the



postremission therapy, whereby patients who fail to achieve MRD negativity can be transplanted in first CR. In addition to the MRD status, new genomic and immunophenotyping technologies were essential in identifying patients with poor prognosis. Patient with Ph-like ALL and ETP-ALL should be considered for AHSCT in first CR (24,54).

### Minimal Residual Disease

Postinduction assessment for persistence or reemergence of MRD in patients with ALL is the most important adverse prognostic factor and identifies chemorefractory disease (64, 66, 67). Virtually all adults with ALL and molecular failure exhibit poor prognosis despite continued chemotherapy and are candidates for stem-cell transplantation and targeted therapies (68).

The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial in adolescent and adult patients with high-risk Ph-negative ALL showed poor MRD clearance by FCM after early consolidation and identified the pattern of MRD clearance as the only prognostic factor for DFS and OS (69).

Blinatumomab is a bispecific T-cell engaging (BiTE) antibody and is the first agent in its class that engages host T cells to the target cell surface antigen-expressing cancer cells. It contains the variable domains of a CD19 and a CD3 antibody, joined via nonimmunogenic linker (70). Cytotoxic T cells are activated upon binding to CD19, inducing cell death through the perforin system. Given the pharmacokinetics of the construct (short half-life and the mechanism of action), continuous infusion over several weeks resulted in significantly improved drug activity in ALL and minimization of side effects. Twenty-one patients in hematologic and morphologic CR with persistent or reappearing MRD during consolidation were first studied with a blinatumomab dose of 15  $\mu\text{g}/\text{m}^2/\text{d}$  as a continuous infusion for 28 days every 6 weeks for a total of 4 cycles or proceeded to AHSCT if a donor was available (71). Minimal residual disease conversion following one cycle of therapy was seen in 80% of patients. After a median follow-up of 33 months, 60% of patients remained in CR, with the same percentage of patients experiencing estimated 3-year refractory-free survival (72). Nontransplanted patients had a similar favorable outcome compared to the nine patients who underwent AHSCT.

A recent confirmatory, open-label, multicenter, phase II trial of blinatumomab in 116 patients with MRD-positive B-cell precursor ALL in CR resulted in overall MRD eradication in 80% of patients, almost all (78%) after a single cycle of therapy (73). As a result, the MD Anderson Cancer Center (MDACC) will open a trial evaluating the role of blinatumomab in patients with positive MRD in CR.

## SALVAGE THERAPY

The prognosis of adult patients with relapsed ALL remains poor, with limited effective therapies available. Relapsed disease carries a median survival of only 24 weeks, and patients who have short duration of first CR or primary refractory disease do particularly poorly, with a median OS of less than 5 months (74). The goal of salvage therapy is to reinduce CR and consolidate with an AHSCT. Given that we currently lack agents or regimens that can singularly achieve cure in the relapsed setting, patients should be enrolled on a clinical trial if possible. Choice of salvage is contingent upon the previous treatment history, remission duration, ongoing comorbidities, and the relapse-specific features that may be targetable.

Asparaginase could be incorporated into salvage for patients without previous exposure to it. This can be achieved through the augmented HCVAD protocol designed at MDACC, which intensifies the standard vincristine and corticosteroid backbone and adds the pegylated asparaginase (75). In an initial study, 80% of 88 evaluable patients initially received conventional HCVAD and 76% were receiving this regimen in first salvage. The ORR was 64%; 47% of patients achieved CR, whereas the remainder achieved partial response (PR) or CRp. Twenty-eight patients (32%) underwent AHSCT, 19 of whom were in CR at the time of transplantation. Despite the favorable response rate, median OS was 6 months, with some long-term responders. As such, regardless of whether they have received conventional HCVAD previously, this regimen represents a reasonable choice for relapsed patients with good performance status who can tolerate intensive chemotherapy.

Clofarabine is a new-generation purine nucleoside analog modeled after fludarabine and cladribine that is approved as a third-line therapy for pediatric ALL (76). Attempts have been made in both pediatric and adult population to build on its modest activity as a single agent by combining it with other chemotherapeutics (77-79). In a phase II multicenter study evaluating clofarabine added to cyclophosphamide and etoposide in 25 heavily relapsed refractory pediatric patients, ORR was 44% (7 patients with CR), and 10 patients eventually underwent AHSCT (77). Patients with prior AHSCT were excluded due to a high rate of veno-occlusive disease (VOD). In the adult population, a French group evaluated clofarabine in patients with relapsed ALL by combining it with dexamethasone, mitoxantrone, etoposide, and asparaginase (VANDEVOL,  $n = 37$ ) or with cyclophosphamide (ENDEVOL,  $n = 18$ ) (78). Complete remission was achieved in 41% and 50% of patients, respectively, and less than one-third of patients received subsequent AHSCT. The median OS was 6.5 months. The PETHEMA group reported on 31 heavily pretreated relapsed/refractory

adult ALL patients, of whom 84% had received two or more previous treatment regimens<sup>(79)</sup>. Complete remission was achieved in 26% of patients, with a median OS of approximately 3 months.

Nelarabine is soluble prodrug of 9- $\beta$ -D-arabinofuranosylguanine and is approved as a nucleoside analog. It has predominant activity in patients with relapsed T-ALL who have failed two prior regimens. By selectively accumulating in T cells, it lends itself as particularly useful in this subset of patients. The GMALL group analyzed 126 patients with relapsed T-ALL/lymphoma who received two cycles of nelarabine as a single agent, with a goal to consolidate patients in CR with AHSCT (partial responders appeared to have potential to achieve CR with continued therapy)<sup>(80)</sup>. After one to three cycles, the CR rate was 36%, with 80% receiving AHSCT. Median OS for the entire cohort was only 6 months, with a 12% probability of survival at 3 years; those who underwent AHSCT after CR had a far better outcome, with a 3-year OS probability of 36%. The major toxicity of nelarabine is neurotoxicity; however, this study noted a low rate of grade 3/4 neurotoxicity, even in patients with prior heavy exposure to vincristine. Nelarabine remains a viable salvage option, and its use continues to be optimized in the frontline combination setting or with alternative dosing schedules<sup>(81)</sup>.

Vincristine is a standard component of almost all regimens in both adult and pediatric ALL and is frequently capped at 2 mg due to compromising dose-limiting neurotoxicity manifested as peripheral neuropathy or moderate to severe constipation. In an effort to optimize its pharmacodynamics and delivery, a liposomal formulation was synthesized. A phase II study evaluated 65 patients with relapsed and refractory ALL with vincristine sulfate liposome administered as a weekly intravenous infusion at 2.25 mg/m<sup>2</sup> with no capping parameter<sup>(82)</sup>. In this heavily pretreated population, the ORR was 35%, and 12 patients underwent AHSCT. Grade 3 peripheral neuropathy was observed in 15% of patients, and the median OS was 4.6 months (five patients were alive at 12 months).

## NOVEL STRATEGIES WITH IMMUNOTHERAPY

### Monoclonal Antibodies

Further intensification of conventional regimens has been limited by unfavorable toxicity/antileukemic profile. The development of monoclonal antibodies directed against cell surface antigens that are better tolerated has since led to significant improvement in outcomes for a number of malignancies, including ALL.

Blinatumomab, a bispecific antibody (anti-CD3 and anti-CD19), was studied in patients with relapsed/refractory ALL as a continuous infusion for 28 days every 6 weeks. The ORR (CR or CRp) with two cycles of therapy was 68%, with an estimated median OS of 9 months<sup>(83)</sup>. In an open-label, single-arm, multicenter phase II study in 189 patients with relapsed/refractory disease, the ORR was 43%, with 80% of the responses during the first cycle. The median response duration and OS were 9 and 6 months, respectively<sup>(84)</sup>. Blinatumomab causes constitutional symptoms (fever, chills) that coincide with a rapid rise in activated T cells, leading to secondary cytokine release syndrome (CRS) that occurs shortly after the start of therapy<sup>(85)</sup>. It can be mitigated with the short course of steroids. Blinatumomab is currently being evaluated in a phase II study in patients with relapsed Ph-positive ALL and in a phase III trial in patients with ALL in first or second relapse (blinatumomab vs investigator's choice of therapy). In a priority review designated by the US Food and Drug Administration, blinatumomab was granted accelerated approval in December 2014 for the treatment of patients with Ph-negative, relapsed or refractory B-ALL.

Inotuzumab ozogamicin is a CD22 immunoconjugate linked to calicheamicin, which is a potent cytotoxic inducer of double-strand DNA breaks. A single-institution phase II study of inotuzumab in 49 patients with highly relapsed/refractory ALL (73% receiving two or more salvage therapies) treated every 3 to 4 weeks resulted in an ORR of 57%, with a median OS of 5.1 months. Survival was comparable between patients who underwent a subsequent AHSCT and those who did not. Serious toxicity in the transplant group included the development of VOD in five patients (23%), although four of these patients had multiple prior alkylating therapies. A modified weekly dosing schedule developed based on preclinical studies yielded a similar ORR to the single-dose schedule (59% vs 57%), with a median survival of 9.5 months. This mode of delivery was less toxic, and hepatotoxicity was also significantly reduced, including a 7% incidence of VOD after autologous stem cell transplantation. An additional multicenter phase I/II study of 37 patients with relapsed/refractory ALL, in which 54% of patients were receiving two or more salvage therapies, also evaluated weekly inotuzumab. The CR and CRp rates were 79% (19/24) and 46% (6/13) in the dose-expansion and dose-escalation cohorts, respectively. Among the responders, 22 patients achieved MRD negativity. Furthest along in the development process, inotuzumab was investigated and compared in a randomized trial to physician's choice of therapy in patients with ALL in first and second salvage. Early results have shown a significant improvement in the response rate (CR/CR with incomplete hematologic

recovery) favoring inotuzumab versus standard-of-care intensive chemotherapy (80.7% vs 33.3%,  $P < .0001$ )<sup>(86)</sup>. Survival data are maturing.

### Chimeric Antigen Receptor T Cells

Autologous T cells can be engineered to express a receptor directed at CD19. Response can be durable given the ability of T cells to expand and persist in vivo. As such, chimeric antigen receptor (CAR) T cells have become an effective approach for targeting lymphoid malignancies<sup>(87, 88)</sup>. In a pilot study with 25 children and 5 adults who were treated for relapsed/refractory ALL with CTL019, 27 patients (90%) achieved CR, with 6-month EFS and OS rates of 67% and 78%, respectively<sup>(89)</sup>. In a recent phase I trial of 21 children and young adults with relapsed/refractory ALL treated with CAR T cells after lymphodepletion, 21 evaluable patients (70%) achieved CR, with 12 (60%) achieving MRD negativity. At a median follow-up of 10 months, the OS rate was 52%<sup>(90)</sup>. In another study

of relapsed refractory ALL with antecedent detectable disease before T-cell infusion, 14 patients (88%) showed response, 10 (63%) with CR and 4 (25%) with CRp. Overall, 75% of treated patients achieved MRD negativity<sup>(91)</sup>. Patients responding to this form of therapy invariably develop some degree of CRS, which is usually very manageable with steroids or tocilizumab. Ongoing research is trying to identify the most optimal use of this innovative therapeutic strategy.

### EMERGING THERAPIES: MD ANDERSON APPROACH

A number of innovative therapies for various stages of disease, tailored to risk-adapted strategies, are transforming the treatment of adult ALL and are beginning to result in significant improvements in long-term outcomes. There are several ongoing trials available for patients with ALL at our institution and elsewhere in the frontline and salvage setting (Table 1-6). Our

**Table 1-6 Ongoing Trials at MD Anderson Cancer Center and Elsewhere Available for Patients With ALL (Frontline and Salvage Setting)**

ALL Subgroup	Trial Characteristics	
	Frontline Setting	Salvage Setting
Pre-B-cell ALL	Age <40 years 1. Ofatumumab + augmented BFM Age 40-59 years 1. Hyper-CVAD + ofatumumab 2. Hyper-CVAD + liposomal vincristine Elderly (≥60 years) 1. Mini-hyper-CVD + inotuzumab	1. Mini-hyper-CVD + inotuzumab 2. Low-dose inotuzumab (0.9 mg/m <sup>2</sup> ) 3. Chimeric antigen receptor (CAR) T-cell therapies
Pre-B-cell ALL, MRD+ disease	Blinatumomab	
T-cell ALL	Hyper-CVAD + nelarabine	
Burkitt leukemia, de novo or relapsed refractory	1. Dose-adjusted EPOCH + ofatumumab/rituximab 2. Hyper-CVAD + ofatumumab	
Philadelphia-positive ALL	Hyper-CVAD + ponatinib	Inotuzumab + bosutinib
Philadelphia-like ALL		A phase II study assessing the combination of ruxolitinib or dasatinib + chemotherapy for refractory/relapsed disease
Mixed phenotype acute leukemia (MPAL), de novo and relapsed	Clofarabine, idarubicin, cytarabine, vincristine, and corticosteroid +/- rituximab	
Novel treatment strategies	1. Nelarabine (single-agent) continuous infusion 2. BMS-906024 (NOTCH inhibitor) 3. Ibrutinib 4. Intrathecal rituximab in patients with lymphoid malignancies involving the central nervous system	

BFM, Berlin-Frankfurt-Münster; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; CVD, cyclophosphamide, vincristine, dexamethasone; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; MRD, minimal residual disease.

**Table 1-7 MD Anderson Cancer Center Choice of Therapy for ALL Subtypes**

Subtype of ALL	Therapy
Pre-B-cell ALL CD20 <sup>+</sup>	Hyper-CVAD + ofatumumab
T-cell ALL	Hyper-CVAD + nelarabine
Elderly (≥60 years) B-cell ALL	Mini-hyper-CVD + inotuzumab
Burkitt lymphoma/ leukemia	Hyper-CVAD + ofatumumab/ Dose adjusted EPOCH-ofatumumab/ rituximab
Ph-positive ALL	Hyper-CVAD + ponatinib
Ph-like-positive ALL	Chemotherapy + ruxolitinib/ dasatinib
Mixed phenotype acute leukemia	Clofarabine, idarubicin, cytarabine, vincristine, corticosteroids +/- rituximab
Adolescent and young adult	Hyper-CVAD + ofatumumab Augmented BFM + ofatumumab

CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone;  
CVD, cyclophosphamide, vincristine, dexamethasone; EPOCH, etoposide,  
prednisolone, vincristine, cyclophosphamide, doxorubicin.

choice of therapy for particular ALL subtypes is outlined in [Table 1-7](#).

## CONCLUSION

Therapeutic capabilities in adult ALL have rapidly reached new heights over the past decade with the introduction of highly promising monoclonal antibodies, immune conjugates, CAR T cells, and new-generation TKIs. Rituximab has repeatedly been shown to improve OS, and blinatumomab and inotuzumab have demonstrated significant activity in a highly relapsed/refractory population. Genomic profiling has identified new prognostic markers (eg, *IKZF1*), as well as new therapeutic targets (eg, ABL, JAK, ETV6-NTRK3) that are amenable to targeted therapies that can improve the adverse prognosis of Ph-like ALL. As many of the newer agents advance through the final stages of development, we will be seeking to determine optimal combination and order of delivery and the role of cytotoxic chemotherapy in the safest achievement of durable cure rates. Although the role of these agents still continues to be defined, frontline introduction of most effective therapies can be expected to increase the rate of MRD negativity, optimizing responses and closing the outcome gap separating pediatric from adult ALL. Harnessing the full potential of the immune system with the durable presence of autologous T-cell constructs may ultimately lead to obviation of stem cell transplantation in search of better cure rates in adult ALL.

## REFERENCES

- American Cancer Society. *American Cancer Society: Cancer Facts and Figures 2014*. Atlanta, GA: American Cancer Society; 2014.
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin*. 62(1):10-29. doi:10.3322/caac.20138.
- Lightfoot TJ, Roman E. Causes of childhood leukaemia and lymphoma. *Toxicol Appl Pharmacol*. 2004;199(2):104-117. doi:10.1016/j.taap.2003.12.032.
- Richardson RB. Promotional etiology for common childhood acute lymphoblastic leukemia: the infective lymphoid recovery hypothesis. *Leuk Res*. 2011;35(11):1425-1431. doi:10.1016/j.leukres.2011.07.023.
- Chevalier SA, Durand S, Dasgupta A, et al. The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties. *PLoS One*. 2012;7(7):e41003. doi:10.1371/journal.pone.0041003.
- Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. *Cell*. 1987;49(2):161-170.
- Vianna NJ, Polan AK. Childhood lymphatic leukemia: prenatal seasonality and possible association with congenital varicella. *Am J Epidemiol*. 1976;103(3):321-332.
- Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. *Hematol Oncol Clin North Am*. 2001;15(1):145-162.
- Faderl S, O'Brien S, Pui C-H, et al. Adult acute lymphoblastic leukemia: concepts and strategies. *Cancer*. 2010;116(5):1165-1176. doi:10.1002/cncr.24862.
- Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol*. 1999;17(12):3835-3849.
- Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. *Haematologica*. 1997;82(1):64-66.
- Preti HA, Huh YO, O'Brien SM, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. *Cancer*. 1995;76(9):1564-1570.
- Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. *Blood*. 1998;92(3):795-801.
- Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. *J Clin Oncol*. 1998;16(12):3768-3773.
- Serrano J, Román J, Sánchez J, Torres A. Myeloperoxidase gene expression in acute lymphoblastic leukaemia. *Br J Haematol*. 1997;97(4):841-843.
- Faber J, Kantarjian H, Roberts MW, Keating M, Freireich E, Albitar M. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. *Arch Pathol Lab Med*. 2000;124(1):92-97. doi:10.1043/0003-9985(2000)124<0092:TDTNAL>2.0.CO;2.
- Foa R, Vitale A. Towards an integrated classification of adult acute lymphoblastic leukemia. *Rev Clin Exp Hematol*. 2002;6(2):181-202.
- Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. *Blood*. 2009;113(25):6330-6337. doi:10.1182/blood-2008-04-151860.
- Onciu M, Lai R, Vega F, Bueso-Ramos C, Medeiros LJ. Precursor T-cell acute lymphoblastic leukemia in adults: age-related immunophenotypic, cytogenetic, and molecular subsets. *Am J Clin Pathol*. 2002;117(2):252-258. doi:10.1309/08DJ-GPBH-H0VR-RC6F.

20. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. *Blood*. 2005;105(9):3434-3441. doi:10.1182/blood-2004-07-2922.
21. Kohlmann A, Schoch C, Schnittger S, et al. Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. *Leukemia*. 2004;18(1):63-71. doi:10.1038/sj.leu.2403167.
22. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell*. 2002;1(1):75-87.
23. Yeoh E-J, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell*. 2002;1(2):133-143.
24. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. *Lancet Oncol*. 2009;10(2):125-134. doi:10.1016/S1470-2045(08)70339-5.
25. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med*. 2014;371(11):1005-1015. doi:10.1056/NEJMoa1403088.
26. Harvey RC, Mullighan CG, Chen I-M, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*. 2010;115(26):5312-5321. doi:10.1182/blood-2009-09-245944.
27. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. *Clin Cancer Res*. 2002;8(7):2217-2224.
28. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell*. 2012;22(2):153-166. doi:10.1016/j.ccr.2012.06.005.
29. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. *Cancer*. 2006;106(7):1569-1580. doi:10.1002/cncr.21776.
30. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer*. 2004;101(12):2788-2801. doi:10.1002/cncr.20668.
31. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. *J Clin Oncol*. 2000;18(3):547-561.
32. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med*. 2006;354(2):166-178. doi:10.1056/NEJMra052603.
33. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. *Blood*. 2014;124(26):3870-3879. doi:10.1182/blood-2014-03-563627.
34. Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002. *Br J Haematol*. 2014;165(1):102-111. doi:10.1111/bjh.12736.
35. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. *N Engl J Med*. 2013;369(20):1915-1925. doi:10.1056/NEJMoa1308392.
36. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. *J Clin Oncol*. 2010;28(24):3880-3889. doi:10.1200/JCO.2009.26.9456.
37. Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. *Blood Rev*. 2012;26(1):25-32. doi:10.1016/j.blre.2011.08.001.
38. Jabbour E, Kantarjian H, Thomas D, et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia. *Blood*. 2013;122:2664.
39. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. *Biol Blood Marrow Transplant*. 2013;19(1):150-155. doi:10.1016/j.bbmt.2012.08.021.
40. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. *J Clin Oncol*. 2010;28(22):3644-3652. doi:10.1200/JCO.2010.28.1287.
41. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. *Blood*. 2014;123(6):843-850. doi:10.1182/blood-2013-09-529008.
42. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as frontline therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). *Blood*. 2006;108(5):1469-1477. doi:10.1182/blood-2005-11-4386.
43. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. *Nat Genet*. 2004;36(5):453-461. doi:10.1038/ng1343.
44. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. *Blood*. 2010;116(12):2070-2077. doi:10.1182/blood-2009-12-261586.
45. Chalandon Y, Thomas X, Hayette S, et al. Is less chemotherapy detrimental in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with high-dose imatinib? Results of the prospective randomized GRAAPH-2005 study. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA.
46. Rousselot P, Coude MM, Huguet F, et al. Dasatinib and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study. Paper presented at: 54th Annual Meeting of the American Society of Hematology; December 8-11, 2012; Atlanta, GA.
47. Ottman OG, Pfeifer H, Cayuela JM, et al. Nilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL-PH-02). *Blood*. 2014;124:798.
48. Chiaretti S, Vitale A, Elia L, et al. First results of the multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) patients. *Blood*. 2014;124:797.
49. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2012;367(22):2075-2088. doi:10.1056/NEJMoa1205127.
50. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2013;369(19):1783-1796. doi:10.1056/NEJMoa1306494.
51. O'Brien S, Jabbour E, Thomas D, et al. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia. *J Clin Oncol*. 2013;31(suppl):7024.
52. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia